Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Johnson and Johnson show Remicade to ‘significantly reduce’ bowel surgery

Johnson and Johnson show Remicade to ‘significantly reduce’ bowel surgery

17th October 2007

Johnson & Johnson (J&J) has presented clinical data which shows that the use of Remicade “significantly reduces” the incidence of colectomy surgeries in ulcerative colitis patients.

The data, presented at the American College of Gastroenterology (ACG), demonstrated a 43 per cent reduction in the incidence of colectomy, the surgical removal of the colon, in patients receiving Remicade for 54 weeks.

Trials, entitled the Active Ulcerative Colitis One and Two Trials (ACT trials), comprised of 728 patients with 630 of those patients completing follow-up to determine whether they underwent colectomy surgery.

Commenting on the results, Paul Rutgeert from University Hospital Gasthuisberg in Leuven, Belgium, stated: “Remicade may offer patients who fail other therapies the possibility of avoiding costly surgeries and hospitalisations while managing the symptoms of this debilitating disease long-term.”

Separate data presented at the ACG showed that colectomy surgery on ulcerative colitis patients increased the total utilisation of health care services with surgery increasing the frequency of inpatient and outpatient hospital procedures, emergency room and physician visits, and laboratory and drug costs.

Earlier this year, J&J subsidiary Centocor announced the analysis of data from a clinical study of Remicade (infliximab) in patients with severe psoriasis.

The results showed that three-quarters of patients exhibited a 75 per cent improvement in symptoms measured by the Psoriasis Area Severity Index, while those patients with psoriasis affecting the nails also showed significant improvements in their symptoms.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.